NASDAQ:AMRS Amyris - AMRS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amyris, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.60 +0.04 (+2.56%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.52▼$1.6450-Day Range$1.38▼$2.2352-Week Range$1.25▼$5.31Volume3.91 million shsAverage Volume5.32 million shsMarket Capitalization$528.26 millionP/E RatioN/ADividend YieldN/APrice Target$4.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Amyris MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside191.7% Upside$4.67 Price TargetShort InterestBearish21.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.57) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsBasic Materials Sector101st out of 161 stocksIndustrial Organic Chemicals Industry10th out of 20 stocks 3.0 Analyst's Opinion Consensus RatingAmyris has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.67, Amyris has a forecasted upside of 191.7% from its current price of $1.60.Amount of Analyst CoverageAmyris has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted21.01% of the float of Amyris has been sold short.Short Interest Ratio / Days to CoverAmyris has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Amyris has recently decreased by 1.39%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAmyris does not currently pay a dividend.Dividend GrowthAmyris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMRS. Previous Next 3.1 News and Social Media Coverage News SentimentAmyris has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Basic Materials companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Amyris this week, compared to 3 articles on an average week.Search Interest55 people have searched for AMRS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows18 people have added Amyris to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amyris insiders have not sold or bought any company stock.Percentage Held by Insiders33.80% of the stock of Amyris is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.08% of the stock of Amyris is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amyris are expected to grow in the coming year, from ($1.57) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amyris is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amyris is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmyris has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amyris (NASDAQ:AMRS) StockAmyris, Inc. engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.Read More Receive AMRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRS Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comAmyris (NASDAQ:AMRS) Trading 5.4% Higher January 24, 2023 | seekingalpha.comAmerican Lithium, Yield10 Bioscience among major Energy/Material gainers, Amyris leads losersJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 9, 2023 | finance.yahoo.comBullish Amyris, Inc. (NASDAQ:AMRS) insiders filled their treasuries with US$20m worth of stock over last yearJanuary 4, 2023 | finance.yahoo.comAMYRIS TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTH CARE CONFERENCEDecember 29, 2022 | finance.yahoo.comAMYRIS ANNOUNCES $50 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENTDecember 29, 2022 | seekingalpha.comAmyris: In Danger Of Running Out Of Funds After Delay To Key Strategic TransactionDecember 27, 2022 | finance.yahoo.comSynthetic Biotechnology Company Amyris Reveals Progress In Ingredients Supply TransactionJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 27, 2022 | finance.yahoo.comAMYRIS SUCCESSFULLY ADVANCES STRATEGIC TRANSACTIONDecember 12, 2022 | finance.yahoo.com10 Cheap Small-Cap Stocks to Buy Before the Next BreakoutDecember 10, 2022 | finance.yahoo.comInstitutional investors may adopt severe steps after Amyris, Inc.'s (NASDAQ:AMRS) latest 10% drop adds to a year lossesNovember 30, 2022 | finance.yahoo.comAMYRIS CONSUMER BRANDS DELIVER 80% CYBER MONDAY LIKE-FOR-LIKE GROWTHNovember 28, 2022 | finance.yahoo.comAMYRIS CONSUMER BRANDS DELIVER RECORD BLACK FRIDAY WEEK SALESNovember 9, 2022 | finance.yahoo.comWhy Amyris Stock Was Driven Into the Ground on WednesdayNovember 9, 2022 | finance.yahoo.comAmyris, Inc. (AMRS) Reports Q3 Loss, Misses Revenue EstimatesNovember 8, 2022 | finance.yahoo.comAMYRIS, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTSNovember 1, 2022 | finance.yahoo.comAMYRIS TO HOST THIRD QUARTER 2022 FINANCIAL RESULTS CONFERENCE CALL ON NOVEMBER 8October 25, 2022 | finance.yahoo.comAmyris and World Wildlife Fund Announce Partnership to Protect BiodiversityOctober 24, 2022 | finance.yahoo.comAMYRIS SUCCESSFULLY LAUNCHES TWO NEW CONSUMER BRANDSOctober 17, 2022 | benzinga.comThinking about buying stock in Archaea Energy, Agrify, Milestone Pharmaceuticals, Revlon, or Amyris? - Amyris (NASDAQ:AMRS), Agrify (NASDAQ:AGFY) - BenzingaOctober 14, 2022 | fool.comWhy Amyris Stock Tumbled This Week - The Motley FoolOctober 12, 2022 | finance.yahoo.comAmyris Brands Expanding in UK and Europe. Executing on continued accelerated growth and lower costs - Yahoo FinanceOctober 11, 2022 | streetinsider.comAmyris (AMRS) Brands Expanding in UK and Europe. Executing on continued accelerated growth and lower costs - StreetInsider.comOctober 11, 2022 | finance.yahoo.comAmyris Brands Expanding in UK and Europe. Executing on continued accelerated growth and lower costsOctober 10, 2022 | seekingalpha.comAmyris hits the skids, down 19% over last two trading sessions (NASDAQ:AMRS) - Seeking AlphaOctober 10, 2022 | reuters.comAMRS.O - Amyris Inc | Stock Price & Latest News | ReutersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRS Company Calendar Last Earnings11/08/2022Today1/28/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Industrial organic chemicals Sub-IndustryOil & Gas Refining & Marketing SectorBasic Materials Current SymbolNASDAQ:AMRS CUSIP03236M10 CIK1365916 Webamyris.com Phone(510) 450-0761Fax510-225-2645Employees980Year Founded2003Price Target and Rating Average Stock Price Forecast$4.67 High Stock Price Forecast$6.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+191.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-270,970,000.00 Net Margins-131.70% Pretax Margin-135.65% Return on EquityN/A Return on Assets-43.61% Debt Debt-to-Equity RatioN/A Current Ratio0.88 Quick Ratio0.46 Sales & Book Value Annual Sales$341.82 million Price / Sales1.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book2.00Miscellaneous Outstanding Shares330,160,000Free Float218,565,000Market Cap$528.26 million OptionableOptionable Beta1.11 Social Links Key ExecutivesJohn G. MeloPresident, Chief Executive Officer & DirectorEduardo AlvarezChief Operating OfficerHan KieftenbeldChief Financial & Administration OfficerSunil ChandranSenior Vice President-Research & DevelopmentCharles KraftSVP-Global Manufacturing & Process DevelopmentKey CompetitorsGreen PlainsNASDAQ:GPREGores Holdings VIIINASDAQ:GIIXWestlake Chemical PartnersNYSE:WLKPRanpakNYSE:PACKTaseko MinesNYSE:TGBView All CompetitorsInsiders & InstitutionsState of Michigan Retirement SystemBought 450,000 shares on 1/27/2023Ownership: 2.316%Pinnacle Associates Ltd.Sold 303,140 shares on 1/25/2023Ownership: 1.259%National Bank of Canada FIBought 6,926 shares on 1/24/2023Ownership: 0.000%Wealth Alliance Advisory Group LLCBought 34,350 shares on 1/17/2023Ownership: 0.010%Bank of New York Mellon CorpBought 88,256 shares on 12/8/2022Ownership: 0.286%View All Insider TransactionsView All Institutional Transactions AMRS Stock - Frequently Asked Questions Should I buy or sell Amyris stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRS, but not buy additional shares or sell existing shares. View AMRS analyst ratings or view top-rated stocks. What is Amyris' stock price forecast for 2023? 4 equities research analysts have issued twelve-month target prices for Amyris' stock. Their AMRS share price forecasts range from $2.00 to $6.00. On average, they predict the company's stock price to reach $4.67 in the next twelve months. This suggests a possible upside of 191.7% from the stock's current price. View analysts price targets for AMRS or view top-rated stocks among Wall Street analysts. How have AMRS shares performed in 2023? Amyris' stock was trading at $1.53 at the beginning of 2023. Since then, AMRS stock has increased by 4.6% and is now trading at $1.60. View the best growth stocks for 2023 here. When is Amyris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our AMRS earnings forecast. How were Amyris' earnings last quarter? Amyris, Inc. (NASDAQ:AMRS) issued its quarterly earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.25. The biotechnology company earned $71.13 million during the quarter, compared to analysts' expectations of $111.98 million. When did Amyris' stock split? Amyris's stock reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What guidance has Amyris issued on next quarter's earnings? Amyris issued an update on its fourth quarter 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $100.00M-, compared to the consensus revenue estimate of $138.39 million. What is John Melo's approval rating as Amyris' CEO? 84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend. What other stocks do shareholders of Amyris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA). What is Amyris' stock symbol? Amyris trades on the NASDAQ under the ticker symbol "AMRS." Who are Amyris' major shareholders? Amyris' stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Michigan Retirement System (2.32%), Pinnacle Associates Ltd. (1.26%), Wealth Alliance Advisory Group LLC (0.01%) and National Bank of Canada FI (0.00%). Insiders that own company stock include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, James F Mccann, John Melo, L John Doerr and Nicole Kelsey. View institutional ownership trends. How do I buy shares of Amyris? Shares of AMRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amyris' stock price today? One share of AMRS stock can currently be purchased for approximately $1.60. How much money does Amyris make? Amyris (NASDAQ:AMRS) has a market capitalization of $528.26 million and generates $341.82 million in revenue each year. The biotechnology company earns $-270,970,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis. How many employees does Amyris have? The company employs 980 workers across the globe. How can I contact Amyris? Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The official website for the company is amyris.com. The biotechnology company can be reached via phone at (510) 450-0761, via email at investor@amyris.com, or via fax at 510-225-2645. This page (NASDAQ:AMRS) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.